8-K: Longevity Health Holdings Receives Nasdaq Extension for 20/20 Biolabs Merger

Longevity Health Holdings secures Nasdaq extension to meet initial listing requirements post-merger with 20/20 Biolabs by September 2, 2025.

Summary

• Longevity Health Holdings (XAGE) announced that Nasdaq has granted the company an extension to maintain its listing, contingent on meeting initial listing requirements after the proposed merger with 20/20 Biolabs.
• The Nasdaq Hearings Panel approved the extension following a review of XAGE's business developments, financial disclosures, and the proposed merger.
• XAGE plans to complete the merger with 20/20 Biolabs and demonstrate compliance with Nasdaq's initial listing rules by September 2, 2025.
• The company previously effected a 1-for-30 reverse stock split on May 12, 2025, and filed the S-4 registration statement for the merger on May 8, 2025.
• The merger aims to combine XAGE's focus on longevity and healthy aging with 20/20 Biolabs' innovative laboratory tests for early disease detection.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company received an extension, it is conditional and involves risks. The management's comments are optimistic, but the forward-looking statements include numerous risk factors.

Positives

• Nasdaq's decision to grant an extension provides Longevity Health Holdings with additional time to complete the merger and meet listing requirements.
• The merger with 20/20 Biolabs could create a stronger combined company with a broader range of products and services in the longevity and health diagnostics space.
• The company has already taken steps to address Nasdaq's listing requirements, including effecting a reverse stock split.

Negatives

• The extension is conditional, and failure to meet Nasdaq's initial listing requirements by September 2, 2025, could result in delisting.
• The company faces risks related to the completion of the merger, including obtaining stockholder approval and regulatory approvals.
• The company's stock price could be affected by the uncertainty surrounding the merger and its ability to meet Nasdaq's listing requirements.

Risks

• Failure to satisfy the conditions for closing the merger, including obtaining stockholder approval.
• Uncertainties regarding the timing of the merger and the ability of each company to consummate the merger.
• Risks related to XAGE's ability to maintain its Nasdaq listing and manage operating expenses.
• Failure or delay in obtaining required governmental approvals for the merger.
• Potential adverse reactions or changes to business relationships resulting from the merger announcement or completion.
• Inability of the combined company to obtain sufficient additional capital.
• Failure to realize anticipated benefits of the merger.
• Diversion of management's attention from ongoing business.
• Risk of unknown liabilities arising after the merger.
• The possibility that the company may be adversely affected by other economic, business, and/or competitive factors.

Future Outlook

The company is focused on completing the merger with 20/20 Biolabs and demonstrating compliance with Nasdaq's initial listing rules by September 2, 2025. The combined company aims to advance its mission to deliver innovative longevity solutions.

Management Comments

• Rajiv Shukla, Chairman and Chief Executive Officer of XAGE, stated, 'We are pleased to have received the Panel's decision and remain focused on completing our merger with 20/20 BioLabs.'
• Rajiv Shukla also stated, 'We thank our stockholders and partners for their continued support as we execute our growth strategy and advance our mission to deliver innovative longevity solutions.'

Industry Context

The merger reflects a trend of consolidation in the health and wellness industry, with companies seeking to expand their product offerings and market reach. Longevity and early disease detection are growing areas of interest in the healthcare sector.

Comparison to Industry Standards

• It is difficult to compare the results to industry standards as the document is about a Nasdaq listing extension.
• However, other companies in the biotech and healthcare sectors, such as Novavax and Cassava Sciences, have faced similar challenges with Nasdaq compliance, often requiring reverse stock splits or other measures to maintain their listings.
• The merger strategy is similar to that of other companies seeking to diversify their product portfolios and achieve economies of scale.

Stakeholder Impact

• Shareholders are impacted by the potential dilution from the merger and the reverse stock split.
• Employees of both companies may experience uncertainty during the merger process.
• Customers may benefit from a broader range of products and services offered by the combined company.

Next Steps

• Longevity Health Holdings must complete the merger with 20/20 Biolabs.
• The combined company must demonstrate compliance with Nasdaq's initial listing rules by September 2, 2025.
• The company needs to obtain stockholder approval for the merger.
• The company needs to obtain required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed Merger.

Key Dates

Keywords

merger, Nasdaq listing, 20/20 Biolabs, Longevity Health Holdings, reverse stock split, compliance, extension